They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Gardasil was 13% of Merck's sales in 2024, and roughly half of Gardasil sales tie to China. This increases reliance on Merck's oncology drug Keytruda (46% of sales), which could face biosimilar ...

The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...

Gardasil vaccine protects against cancer-causing ... Analysts had been projecting earnings of $9.13 per share on $67.07 billion in sales, according to FactSet. For the recently completed fourth ...

Merck reported a 2% decline in Gardasil sales, after reaching a peak of $8.9 billion in 2023. Now with shipments to China paused, the HPV vaccine faces significant headwinds going into 2025.

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...